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We are interested in characterizing the cellular machinery
involved in the restriction of retrovirus replication - the
components of the innate or ''intrinsic'' immunity. Stud-
ies of two such systems will be presented. In the first
example, we have identified components involved in tran-
scriptional silencing of proviral DNA by Embryonic Stem
(ES) cells. It has long been known that ES cells potently
block provirus expression via  a transacting factor that
binds to the primer binding site (PBS) for proline tRNA
on the murine leukemia virus genome. We have purified
the silencing complex and identified TRIM28 (Kap-1), a
known transcriptional silencer, as an integral component
of the complex. Further, we have identified the DNA
sequence-specific binding component of the complex as
being ZFP809, one of the dozens of zinc finger proteins
encoded in the mammalian genome. We show that
expression of ZFP809 is sufficient to render even differen-
tiated cells highly resistant to MLV infection. Furthermore,
we demonstrate that ZFP809 is able to potently block
transcription from DNA constructs of human T-cell lym-
photropic virus-1 (HTLV-1), which use the same primer
tRNA. Finally, we found that similar silencing occurs at
the distinct PBS for at least one other tRNA (namely,
Lys1,2) utilized by such viruses as visna and spuma.
In the second example, we have identified a novel antivi-
ral gene that prevents the accumulation of retroviral
mRNAs in the cytoplasm. The gene, designated ZAP,
encodes a CCCH-type zinc finger antiviral protein. A
region near the 3' end of the Moloney MuLV RNA was
identified as necessary and sufficient to provide sensitivity
to ZAP and to target mRNAs for loss. ZAP did not affect
nuclear RNA levels but dramatically shortened the half-
life of the viral RNAs in the cytoplasm. ZAP also potently
inhibited HIV-1 RNA accumulation. ZAP was tested for its
ability to inhibit viruses from other families and was
found to potently inhibit the replication of multiple
members of the alphavirus genus, including Sindbis, Sem-
liki Forest, Ross River, and Venezuelan equine encephali-
tis viruses. As for retroviruses, the major block to Sindbis
RNA accumulation could be localized to a small portion
of the genome. Recombinant ZAP was found to bind spe-
cifically to the viral RNAs in vitro, and binding efficiency
correlated well with restriction activity. ZAP binds to a sin-
gle subunit of the RNA exosome, the major cellular
machinery for RNA turnover, suggesting that it brings the
exosome to the target RNAs to degrade them.
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